-
2 killed, 13 wounded in bus blast near Syrian capital: state media
-
Real Madrid extend Vinicius deal, sign Diomande in title bid boost
-
All Blacks skipper Taylor cautiously recovering from calf strain
-
PSG sign France midfielder Akliouche from Monaco
-
UN chief denounces Russia, Ukraine for civilian deaths
-
CONMEBOL 'expresses concern regarding repeated unilateral actions' by FIFA
-
UEFA turn up the pressure on Infantino and repeat boycott threat
-
Warren coy over whether Fury-Joshua will be in UK or US
-
Rodri approves Barcelona transfer talks with Man City: Barca source to AFP
-
Taiwan blocks key bridge in drill for potential Chinese invasion
-
Venezuela unable to tally missing from cataclysmic quakes
-
Migrant children risk abuse on streets of Ceuta, aid groups warn
-
Le Court sprints to stage six Tour de France Femmes win
-
Oil price shoots up as stocks tread water
-
Doping body says Parker's positive cocaine test caused by nutritionist
-
British Grand Prix stays on MotoGP calendar until 2028
-
UEFA says boycott of World Cups stands despite FIFA backdown on private investment
-
Britain's EasyJet flies into US hands as takeover confirmed
-
Rheinmetall sales keep surging despite cancelled naval frigate project
-
Real Madrid sign Ivory Coast winger Yan Diomande
-
Pogacar teammate Del Toro gets new UAE deal after Tour podium
-
How online disinformation fuelled Ceuta migrant surge
-
Stocks tread water with earnings, tech in focus
-
Inevitable AI Group Raises $6M From Aleph to Launch AI-Native SaaS Companies
-
Forex Expo Dubai Announces Opportunity to Win Up to 150 Grams of Gold This September 2026
-
Suspected Ebola death on boat heading for DR Congo capital
-
Forlan named new Uruguay head coach
-
England selector North not 'hung up' on Stokes absence
-
UEFA chief Ceferin: 'Underdog' leader taking fight to FIFA's Infantino
-
UK Anti-Doping confirm former world champ Parker's ban lifted
-
Salah completes move to Turkey's Trabzonspor
-
French winemakers dread 'smoky taste' after wildfires
-
UK clears Paramount's takeover of Warner Bros
-
Stocks diverge with earnings, tech in focus
-
North Korea fires ballistic missile: South Korea military
-
England recall batsman Lawrence for Pakistan series
-
'Don't have to hide': Thai IDs, legal work give hope to Myanmar refugees
-
Siemens shares plunge on disappointing guidance raise
-
Stocks mixed with tech firms back under pressure
-
New Australia coach Kiss gives Japan starts to Ross, Amatosero
-
How Blundell's old school tactic ended England's 'Bazball' era
-
'Stretch our money': Romanians face highest EU inflation
-
Israel reports troop deaths as Lebanon talks underway in Rome
-
Iran says close to Hormuz plan with Oman, but reopening depends on US
-
Seeds Rybakina, Pegula, Gauff reach third round at WTA Toronto
-
Messi scores twice to set Leagues Cup record in Miami victory
-
Police raid South Korea FA in probe into World Cup coach appointment
-
Asian stocks mostly down with tech firms back under pressure
-
Low water on Germany's Rhine river threatens new blow to economy
-
Back to the future as world champion Springboks host All Blacks
US drugmaker Eli Lilly says slashing insulin prices by 70%
US pharmaceutical giant Eli Lilly announced Wednesday it was cutting the cost of its most commonly prescribed insulins by 70 percent after years of soaring prices that hit millions of Americans living with diabetes.
The announcement comes as the cost of insulin has surged in recent years, with demand increasing significantly as well.
"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the Indianapolis-based drugmaker said in a statement.
The company added it would cut the price of its non-branded insulin to $25 a vial starting May 1.
It will also lower the price of Humalog, its most commonly prescribed insulin, and Humulin, by 70 percent starting in the fourth quarter of this year.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said Lilly CEO David Ricks.
The company also said Wednesday it would automatically cap out-of-pocket costs at certain retail pharmacies at $35, for people with commercial insurance using Lilly insulin.
Diabetes is one of the fastest-growing chronic diseases globally, according to a 2022 study.
- Soaring prices -
In recent decades, insulin prices have soared in the United States, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.
But the cost of producing insulin is relatively low compared to the sale price.
A survey by nonprofit T1International also showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
In his State of the Union address last month, President Joe Biden said: "Big Pharma has been unfairly charging people hundreds of dollars –- and making record profits. Not anymore."
While seniors on Medicare have the cost of insulin capped, millions of other Americans not on the federal health insurance program for the elderly need insulin to save their lives, he added.
"Let's finish the job this time. Let's cap the cost of insulin at $35 a month for every American who needs it," Biden said.
Diabetes is divided into two types. An estimated nine million people have type 1 diabetes, a chronic condition where the pancreas does not produce enough insulin -- the hormone that regulates blood sugar levels.
Most people living with diabetes have type 2, which is associated with obesity and other lifestyle factors and emerges in adults and increasingly among children.
All type 1 diabetics need insulin to survive, and generally their access is ensured.
Some 63 million people with type 2 also need the hormone, according to World Health Organization estimates, but only about half of them can access it.
O.Bulka--BTB